GCTK Company Profile and Key Details

GlucoTrack, Inc. generated EPS of -$1,359.65 over the past year. Five-year average earnings growth is -18.33%.

GCTK has shown mixed momentum, losing -0.52% over the past week and -42.94% over the past quarter, though year-to-date performance is down -1.81%. Short-term trend indicators are bullishly aligned (SMA20 -4.4%, SMA50 -47.17%, SMA200 -70.99%). The stock’s 14-day RSI is 29.89 (weak momentum), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -94.62% below its high and over 13.89% above its low. Average 10-day trading volume of 17.33 million shares is significantly above the 3-month average of 3.14 million, indicating heightened recent market interest.

GlucoTrack, Inc. has 899.41 thousand shares outstanding. The public float is 850.27 thousand shares, elevated short interest at 6.30% of float. This equals 32.26 thousand shares. The short ratio is 0.03 days. Institutional investors hold 0.86% of the float. Insiders own 5.55%. SYCOFF DREW holds 138.00 thousand shares, John A. Ballantyne Revocable Living Trust dated 08/01/2017 has 59.26 thousand shares and BALLANTYNE JOHN has 59.26 thousand shares.

GlucoTrack, Inc. (NASDAQ:GCTK) closed at $0.73 USD, losing -$0.01 (-0.82%) from the previous close of $0.74. The stock is currently mid-range between its 52-week high and low $0.62 and $15.90. With a market capitalization of about $414.24 thousand, GlucoTrack, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.61). Key stats such as the average daily volume over the past year has been around 3.03 million shares, volume is running light vs its 52-week average. Headquartered in Or Yehuda, None, GlucoTrack, Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Paul V. Goode, the company employs approximately 11 people and listed since April 25, 2013. GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally.

GlucoTrack, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $14.39. This means the shares are trading below this model’s fair value.

GlucoTrack, Inc. trades at a P/E ratio of -0.03, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.23 suggesting the stock is closer to book value. The P/FCF stands at -0.03, also below market averages.

GlucoTrack, Inc. (NASDAQ:GCTK) shares are flat -1.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows GlucoTrack, Inc. trading at a premium to the broader market with a P/E of -0.03. Our AI forecast model points to short-term strength (1.37% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that GlucoTrack, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.37%, with price expected at $0.74 by May 19, 2026, within a range of $0.64 to $0.83 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by August 03, 2026, with a range of $0.00 to $19.13. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 05, 2027, within a range of $0.00 to $284.43.